Lapine T-Lymphocyte Immune Globulin
Diamond-Blackfan Anemia
Fred Hutchinson Cancer CenterPhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Diamond-Blackfan Anemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Deferasirox Novartis | Phase 4 | BBB |
Fludarabine Fred Hutchinson Cancer Center | Phase 2/3 | BBB |
Busulphan Paul Szabolcs | Phase 2/3 | BBB |
Cyclophosphamide Paul Szabolcs | Phase 2/3 | BB |
Thiotepa Fred Hutchinson Cancer Center | Phase 2 | BB |
View all 24 →
Same molecule, other indications
Lapine T-Lymphocyte Immune Globulin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →